PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
News|Articles|August 31, 2026
Midsized Biotechs Strike MFN Drug Pricing Deals
Author(s)Maggie L. Shaw
Fact checked by: Giuliana Grossi
This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.
Advertisement
Advertisement
Nine midsize pharmaceutical manufacturers have agreed to price outpatient drugs for state Medicaid programs in line with what they charge in other developed countries, the White House announced today,1 extending the administration’s Most Favored Nation (MFN) drug pricing campaign beyond the large drugmakers that have so far signed on to a tier of drugmakers that had largely sat outside these earlier deals.2
Related to this article
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
Advertisement
Advertisement